Publication | Closed Access

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial

VaccinationVaccine DevelopmentVaccine TargetImmunologyInfection ControlPolyvalent VaccineVaccine DesignMedicineVaccine Research